Penumbra Inc (NYSE:PEN) EVP Lynn Rothman sold 5,000 shares of the company’s stock in a transaction on Friday, September 13th. The stock was sold at an average price of $150.02, for a total value of $750,100.00. Following the sale, the executive vice president now owns 12,012 shares of the company’s stock, valued at $1,802,040.24. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.
Lynn Rothman also recently made the following trade(s):
- On Monday, August 19th, Lynn Rothman sold 5,000 shares of Penumbra stock. The shares were sold at an average price of $144.66, for a total value of $723,300.00.
PEN stock traded up $3.23 during midday trading on Friday, hitting $145.94. 301,820 shares of the company’s stock were exchanged, compared to its average volume of 805,482. Penumbra Inc has a 1-year low of $110.84 and a 1-year high of $185.70. The company has a current ratio of 6.23, a quick ratio of 4.33 and a debt-to-equity ratio of 0.10. The business has a 50-day simple moving average of $142.06 and a two-hundred day simple moving average of $149.08. The stock has a market capitalization of $4.95 billion, a PE ratio of 286.16, a P/E/G ratio of 8.21 and a beta of 0.71.
Penumbra (NYSE:PEN) last issued its quarterly earnings data on Tuesday, August 6th. The company reported $0.27 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.21 by $0.06. The business had revenue of $134.20 million during the quarter, compared to analysts’ expectations of $130.67 million. Penumbra had a return on equity of 6.80% and a net margin of 3.03%. The company’s revenue was up 22.4% on a year-over-year basis. During the same period in the previous year, the firm posted $0.15 earnings per share. As a group, research analysts expect that Penumbra Inc will post 0.89 EPS for the current fiscal year.
A number of equities analysts have issued reports on the company. ValuEngine downgraded Penumbra from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. Zacks Investment Research downgraded Penumbra from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. Wells Fargo & Co raised their target price on Penumbra from $180.00 to $185.00 and gave the company an “outperform” rating in a research report on Thursday, August 1st. Finally, Royal Bank of Canada set a $174.00 target price on Penumbra and gave the company a “buy” rating in a research report on Wednesday, August 7th. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $167.14.
Large investors have recently added to or reduced their stakes in the stock. Botty Investors LLC purchased a new position in Penumbra in the first quarter valued at $29,000. Manchester Capital Management LLC purchased a new stake in Penumbra during the 1st quarter worth about $30,000. HM Payson & Co. purchased a new stake in Penumbra during the 2nd quarter worth about $80,000. Machina Capital S.A.S. purchased a new stake in Penumbra during the 2nd quarter worth about $155,000. Finally, CENTRAL TRUST Co purchased a new stake in Penumbra during the 2nd quarter worth about $171,000. Hedge funds and other institutional investors own 85.73% of the company’s stock.
Penumbra, Inc designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, Japan, and internationally. The company offers neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, DDC, and PX SLIM brands; aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the ACE and the 3D Revascularization Device brands.
Receive News & Ratings for Penumbra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra and related companies with MarketBeat.com's FREE daily email newsletter.